External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data

BACKGROUND: A modeling framework was previously developed to simulate overall survival (OS) using tumor growth inhibition (TGI) data from six randomized phase 2/3 atezolizumab monotherapy or combination studies in non-small-cell lung cancer (NSCLC). We aimed to externally validate this framework to...

Descripción completa

Detalles Bibliográficos
Autores principales: Kassir, Nastya, Chan, Phyllis, Dang, Steve, Bruno, René
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363035/
https://www.ncbi.nlm.nih.gov/pubmed/37410154
http://dx.doi.org/10.1007/s00280-023-04558-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363035/
https://www.ncbi.nlm.nih.gov/pubmed/37410154
http://dx.doi.org/10.1007/s00280-023-04558-z

Ejemplares similares